United States Choroidal Neovascularization Drug Market was valued at USD 2.8 Billion in 2022 and is projected to reach USD 4.4 Billion by 2030, growing at a CAGR of 7.0% from 2024 to 2030.
The US Choroidal Neovascularization Drug Market is experiencing significant growth, driven by an increasing demand for effective treatments for age-related macular degeneration (AMD) and other retinal diseases. This market is characterized by a variety of drug types designed to target and treat choroidal neovascularization (CNV), a condition where abnormal blood vessels form beneath the retina, leading to vision impairment. As the prevalence of these conditions rises, the demand for innovative and efficient treatment options is growing exponentially. The drugs available today include biologics, gene therapies, and small molecule treatments that aim to block the growth of abnormal blood vessels and reduce inflammation.
One of the key drivers in the Choroidal Neovascularization Drug Market is the ongoing advancements in biotechnology, which have led to the development of novel therapies. For instance, drugs like ranibizumab and aflibercept, which are anti-VEGF (vascular endothelial growth factor) therapies, have become essential treatments for patients with CNV-related diseases. These treatments have significantly reduced the need for invasive surgeries and have improved the quality of life for many individuals. The rise in biologics is expected to continue as more effective therapies emerge, alongside the growing aging population in the US.
Furthermore, the requirement from industries to innovate and develop drugs with fewer side effects and longer durations of action is intensifying. As pharmaceutical companies push the boundaries of current treatments, they are focusing on improving the efficacy and safety of CNV drugs. The increasing number of clinical trials and research efforts are a testament to this ongoing drive for better solutions. Another emerging trend in the market is the development of combination therapies, where multiple drugs work together to target various aspects of CNV simultaneously, offering a more comprehensive approach to treatment.
In addition to the pharmaceutical companies, the healthcare industry as a whole has a significant role to play in shaping the market. The demand for Choroidal Neovascularization drugs has spurred investment in healthcare infrastructure and technology, facilitating more effective drug delivery methods and improving patient access to treatments. Hospitals, clinics, and research institutions are heavily involved in the distribution and administration of these drugs, further expanding the market's reach.
As more players enter the market and competition intensifies, the need for high-quality, accessible, and affordable treatments will continue to drive the Choroidal Neovascularization Drug Market's expansion. The success of this market will depend on both technological innovations and strategic collaborations across various sectors of the healthcare industry, ensuring that patients receive the best possible care.
Get an In-Depth Research Analysis of the US Choroidal Neovascularization Drug Market Size And Forecast [2025-2032]
Â
Cellphire
Inc
Chrysalis BioTherapeutics
Inc
Cleveland BioLabs
Inc
Cumberland Pharmaceuticals
Inc
Diffusion Pharmaceuticals Inc
Eli Lilly and Company
GNI Group Ltd.
Humanetics Corporation
INSYS Therapeutics
Inc
Meabco A/S
Neumedicines Inc
Onconova Therapeutics
Inc
PharmaIN Corporation
Pluristem Therapeutics Inc
ProCertus BioPharm Inc
RDD Pharma Ltd.
RedHill Biopharma Ltd.
RxBio
Inc
Soligenix
Inc
Â
By the year 2030, the scale for growth in the market research industry is reported to be above 120 billion which further indicates its projected compound annual growth rate (CAGR), of more than 5.8% from 2023 to 2030. There have also been disruptions in the industry due to advancements in machine learning, artificial intelligence and data analytics There is predictive analysis and real time information about consumers which such technologies provide to the companies enabling them to make better and precise decisions. The Asia-Pacific region is expected to be a key driver of growth, accounting for more than 35% of total revenue growth. In addition, new innovative techniques such as mobile surveys, social listening, and online panels, which emphasize speed, precision, and customization, are also transforming this particular sector.
Get Discount On The Purchase of the US Choroidal Neovascularization Drug Market Size And Forecast [2025-2032]
Growing demand for below applications around the world has had a direct impact on the growth of the US Choroidal Neovascularization Drug Market
Anti-VEGF (Vascular Endothelial Growth Factor) Agents
Corticosteroids
Photodynamic Therapy (PDT)
Combination Therapy
Angiogenesis Inhibition
Anti-inflammatory Action
Photochemical Reaction
Intravitreal Injection
Systemic Administration
Topical Application
Hospitals
Specialty Clinics
Ambulatory Surgical Centers
Wet Age-related Macular Degeneration (AMD)
Myopic Choroidal Neovascularization
Diabetic Macular Edema (DME)
Other Retinal Disorders
US (United States, US and Mexico)
Europe (Germany, UK, France, Italy, Russia, Turkey, etc.)
Asia-Pacific (China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Malaysia and Vietnam)
South America (Brazil, Argentina, Columbia, etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
For More Information or Query, Visit @ Choroidal Neovascularization Drug Market Research Analysis
1. Introduction of the US Choroidal Neovascularization Drug Market
Overview of the Market
Scope of Report
Assumptions
2. Executive Summary
3. Research Methodology of Verified Market Reports
Data Mining
Validation
Primary Interviews
List of Data Sources
4. US Choroidal Neovascularization Drug Market Outlook
Overview
Market Dynamics
Drivers
Restraints
Opportunities
Porters Five Force Model
Value Chain Analysis
5. US Choroidal Neovascularization Drug Market, By Type
6. US Choroidal Neovascularization Drug Market, By Application
7. US Choroidal Neovascularization Drug Market, By Geography
US
Europe
Asia Pacific
Rest of the World
8. US Choroidal Neovascularization Drug Market Competitive Landscape
Overview
Company Market Ranking
Key Development Strategies
9. Company Profiles
10. Appendix
About Us: Verified Market Reports
Verified Market Reports is a leading US Research and Consulting firm servicing over 5000+ US clients. We provide advanced analytical research solutions while offering information-enriched research studies. We also offer insights into strategic and growth analyses and data necessary to achieve corporate goals and critical revenue decisions.
Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance using industrial techniques to collect and analyze data on more than 25,000 high-impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.
Contact us:
Mr. Edwyne Fernandes
US: +1 (650)-781-4080
US Toll-Free: +1 (800)-782-1768
Website: https://www.verifiedmarketreports.com/